Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ASCENTAGE PHARMA GROUP INTERNATIONAL
Ascentage Pharma Announces Inclusion of Lisaftoclax in China’s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
November 15, 2026
Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
November 4, 2026
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
November 3, 2026
Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
October 20, 2026
Ascentage Pharma to Participate in Four Upcoming Investor Conferences
September 2, 2026
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
August 19, 2026
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
August 13, 2026
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
August 5, 2026
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
August 5, 2026
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
August 2, 2026
1
2
Next Page
→